MAPK8 and cardiac hypertrophy: Our results reveal that administration of naringenin ameliorates cardiac hypertrophy by inhibiting the activation of JNK, ERK, and phosphatidylinositol-3-kinase/Akt signaling pathways, and it mitigates myocardial fibrosis (Zhang et al., 2015); however, the mechanism underlying the anti-fibrotic effect needs to be clarified.